ORLANDO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today announced that Pawel Kalinski, MD, PhD, Rustum Family Professor for Molecular Therapeutic and Translational Research at Roswell Park Cancer Institute in Buffalo, NY, will be presenting data from preclinical studies and preliminary clinical data on a favorable immune-modulatory activity of Hemispherx’s Ampligen® on the tumor microenvironment, which potentially could help convert “cold” tumors (tumors that are unresponsive to immunotherapy) to tumors that will respond to immunotherapeutic drugs such as checkpoint inhibitors.
Checkpoint inhibitors such as anti-PD-1/PD-L1 agents release effector T cells from immune blockade, thus facilitating an antitumor attack. Checkpoint inhibitors represent a new frontier in immuno-oncology and are on a course to achieve more than $30 billion in sales in the next several years led by Keytruda (Merck) and Opdivo (Bristol Myers). Currently, the effectiveness of these drugs is thought to be limited in part by the ability of the effector T cells to enter the tumor microenvironment (i.e. cold tumors). These findings were the result of a series of experiments that included in vitro, in vivo, and clinical studies.
Dr. Kalinski’s presentation, entitled “Sensitizing Cold Tumors to Immunotherapy: Selectivity and Specificity of Systemic and Local Approaches,” will be given at the Immuno-Oncology Frontiers Conference in Miami, FL on January 24, 2018.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Phone Number: 800-778-4042